10-Q: Axogen Reports 25.6% Revenue Increase in Q2 2024, Progresses with BLA Submission

Axogen, Inc. announced a 25.6% increase in revenue for the second quarter of 2024, alongside advancements in their BLA submission for Avance Nerve Graft.

Summary

• Axogen's revenue for the second quarter of 2024 reached $47.9 million, a 25.6% increase compared to the same period in 2023.
• The company's gross profit for the quarter was $35.3 million, a 19.2% increase year-over-year.
• The increase in revenue was driven by a 15.6% increase in unit volume, a 6.8% increase in product mix, and a 3.2% increase in prices.
• Axogen had 1,042 active accounts as of June 30, 2024, representing a 7% increase from the previous year.
• Core accounts, defined as those purchasing at least $100,000 in the past twelve months, totaled 412, an 18.7% increase year-over-year.
• The company submitted the complete non-clinical data package for the BLA of Avance Nerve Graft in May 2024 and anticipates completing the rolling submission in the third quarter of 2024.
• Axogen believes the BLA submission timeline will allow for a potential approval in mid-2025.
• The company's net loss for the quarter was $1.9 million, an improvement from the $6.7 million loss in the same quarter of 2023.
• The company's cash and cash equivalents and investments totaled $21.1 million as of June 30, 2024.
• Axogen believes its existing cash and cash equivalents, investments, and cash from product sales will fund operations for at least the next 12 months.

Sentiment

Score: 7

Explanation: The document shows positive revenue growth and progress with the BLA submission, but also highlights ongoing losses and debt obligations. The overall sentiment is cautiously optimistic.

Positives

• Revenue increased by 25.6% year-over-year, indicating strong sales growth.
• Gross profit increased by 19.2% year-over-year, showing improved profitability.
• The number of active accounts increased by 7% year-over-year, demonstrating market expansion.
• Core accounts grew by 18.7% year-over-year, indicating increased sales from key customers.
• The company is progressing with the BLA submission for Avance Nerve Graft, with a potential approval in mid-2025.
• The launch of Avive+ Soft Tissue Matrix is expected to drive further growth.
• The net loss decreased significantly compared to the same quarter last year, showing improved financial performance.
• The company believes it has sufficient cash to fund operations for at least the next 12 months.

Negatives

• The company experienced a net loss of $1.9 million for the quarter, although it is an improvement from the previous year.
• Gross margin decreased from 77.7% to 73.8% due to changes in product mix.
• Total costs and expenses, while decreasing slightly, remain high at $35.8 million.
• The company's cash and cash equivalents and investments decreased by $9.9 million from December 31, 2023, primarily due to operating activities.
• The company has a significant amount of debt outstanding under its credit facility.

Risks

• The company's products are subject to regulatory scrutiny, and failure to comply with regulations could impact commercial availability.
• The company is dependent on third-party suppliers for some of its products, and the loss of these suppliers could have a material adverse effect.
• The company is subject to various legal proceedings, which could have a material adverse effect on its financial condition.
• The company's debt obligations include a revenue participation agreement, which could increase interest payments.
• The company's future capital requirements may depend on various factors, and there is no assurance that it will be able to secure funding on acceptable terms.
• The company's debt includes a make-whole payment clause that could result in significant additional costs if the debt is prepaid or held to maturity.
• The company's interest expense increased significantly due to the completion of the APC facility, which is no longer eligible for capitalized interest.

Future Outlook

Axogen expects to drive continued growth within the nerve protection category following the full launch of Avive+ Soft Tissue Matrix and anticipates a potential BLA approval for Avance Nerve Graft in mid-2025. The company believes its existing cash and cash equivalents, investments, and cash from product sales will fund operations for at least the next 12 months.

Management Comments

• We are pleased with the adoption of Axoguard HA+ Nerve Protector across multiple applications.
• We expect to drive continued growth within the nerve protection category following the full launch of Avive+ Soft Tissue Matrix in June of 2024.
• We continue to see strong interest in and adoption of the Resensation neurotization techniques for autologous and implant-based breast reconstructions driven by expanding surgeon education and patient activation.

Industry Context

Axogen operates in the peripheral nerve repair market, which is experiencing growth due to advancements in surgical techniques and an increasing awareness of nerve injuries. The company's focus on innovative, clinically proven, and economically effective repair solutions positions it well within this market. The launch of Avive+ Soft Tissue Matrix and the progress with the BLA submission for Avance Nerve Graft are key developments that could further solidify Axogen's position in the market.

Comparison to Industry Standards

• Axogen's revenue growth of 25.6% in Q2 2024 is strong compared to the broader medical device industry, which typically sees single-digit growth rates.
• Companies like Integra LifeSciences and Stryker, which also operate in the regenerative medicine space, have reported varying growth rates, but Axogen's growth is notable.
• The gross margin of 73.8% is competitive within the medical device industry, although some companies with higher-margin products may achieve higher gross margins.
• The company's focus on nerve repair is a niche market, and direct comparisons to companies with broader product portfolios may not be entirely accurate.
• The BLA submission for Avance Nerve Graft is a significant milestone, and its potential approval could provide a competitive advantage over companies that do not have similar products.

Legal Proceedings

• The Company is and may be subject to various claims, lawsuits, and proceedings in the ordinary course of the Company's business.

Stakeholder Impact

• Shareholders will be impacted by the company's financial performance and progress with the BLA submission.
• Employees will be impacted by the company's growth and expansion plans.
• Customers will benefit from the company's innovative products and solutions.
• Suppliers will be impacted by the company's purchasing activities.
• Creditors will be impacted by the company's debt obligations and financial performance.

Next Steps

• Complete the rolling submission of the BLA for Avance Nerve Graft in the third quarter of 2024.
• Continue to drive adoption of Axoguard HA+ Nerve Protector and Avive+ Soft Tissue Matrix.
• Monitor the FDA review process for the BLA and prepare for potential approval in mid-2025.
• Continue to expand the customer base and sales force.
• Manage debt obligations and monitor interest rate changes.

Key Dates

Keywords

peripheral nerve regeneration, nerve repair, Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Avive+ Soft Tissue Matrix, biologics license application, BLA, revenue growth, medical devices